NCT01887912

Brief Summary

The aim of this study was to evaluate the efficacy of the Clostridium difficile vaccine to prevent primary symptomatic C. difficile infection (CDI) in participants at risk for CDI where there is a substantial unmet medical need. Primary objective:

  • To assess the efficacy of the C. difficile vaccine in preventing the onset of symptomatic primary CDI confirmed by polymerase chain reaction (PCR) in adult participants aged \>= 50 years who are at risk for CDI and have received at least 1 injection. Secondary Objectives: Efficacy:
  • To assess prevention of symptomatic PCR-confirmed primary CDI cases after 3 injections administered at 0, 7, and 30 days.
  • To assess prevention of symptomatic PCR-confirmed primary CDI cases after completion of at least 2 injections. Immunogenicity:
  • To describe the immunogenicity to toxin A and toxin B at specific time points in a subset of participant and in participants with CDI at Day 0 and Day 60. Safety:
  • To describe the safety profile of all participants who received at least 1 injection.

Trial Health

68
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Strong global presence with extensive site network
Enrollment
9,302

participants targeted

Target at P75+ for phase_3

Timeline
Completed

Started Jul 2013

Longer than P75 for phase_3

Geographic Reach
25 countries

334 active sites

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 20, 2013

Completed
7 days until next milestone

First Posted

Study publicly available on registry

June 27, 2013

Completed
1 month until next milestone

Study Start

First participant enrolled

July 30, 2013

Completed
4.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 12, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 12, 2018

Completed
1.1 years until next milestone

Results Posted

Study results publicly available

July 5, 2019

Completed
Last Updated

March 28, 2022

Status Verified

March 1, 2022

Enrollment Period

4.9 years

First QC Date

June 20, 2013

Results QC Date

June 11, 2019

Last Update Submit

March 21, 2022

Conditions

Keywords

Clostridium difficile Toxoid VaccineClostridium difficile infectionCdiffense

Outcome Measures

Primary Outcomes (1)

  • Number of Participants With Symptomatic Polymerase Chain Reaction (PCR)-Confirmed Primary C. Difficile Infection (CDI) Cases

    Symptomatic PCR-confirmed CDI cases were defined as the number of participants with combination of clinical and laboratory findings. Clinical components were: \>= 3 loose stools in \<= 24 hours, loose stools (defined as type 6 \[fluffy pieces with ragged edges, mushy\] or type 7 \[watery, no solid pieces\] according to the Bristol Stool Chart) lasting \>= 24 hours. Laboratory findings were: stool sample positive for C. difficile Toxin B by PCR at central laboratory or diagnosis of pseudomembranous colitis visualized at colonoscopy.

    Up to 3 years post injection 1

Secondary Outcomes (10)

  • Number of Participants With Severe PCR-Confirmed Primary CDI Cases

    Up to 3 years post injection 1

  • Number of Participants With Loose Stool Episodes

    Up to 3 years post injection 1

  • Number of Participants With Symptomatic PCR Confirmed CDI Cases: Per-Protocol Population

    Up to 3 years post injection 1

  • Serum Antibody Concentrations Against Toxins A and B Measured by Enzyme-Linked Immunosorbent Assay (ELISA)

    Day 0, Day 14, Day 30, Day 60, Day 210, Day 390, Day 570, Day 750, Day 930, and Day 1110

  • Percentage of Participants With >= 2 and 4-Fold Rise in Serum Antibody Concentrations From Baseline Against Toxins A and B Measured by ELISA

    Day 60

  • +5 more secondary outcomes

Study Arms (2)

C. difficile Vaccine Group

EXPERIMENTAL

Participants received 1 injection of 0.5 mL C. difficile toxoid vaccine at Days 0 (Injection 1), 7 (Injection 2), and 30 (Injection 3).

Biological: C. difficile Toxoid Vaccine

Placebo Group

PLACEBO COMPARATOR

Participants received 1 injection of 0.5 mL placebo matched to vaccine at Days 0 (Injection 1), 7 (Injection 2), and 30 (Injection 3).

Biological: Placebo: 0.9% normal saline

Interventions

0.5 mL, Intramuscular

C. difficile Vaccine Group

0.5 mL, Intramuscular

Placebo Group

Eligibility Criteria

Age50 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Informed consent form had been signed and dated.
  • Attended all scheduled visits and complied with all trial procedures.
  • Covered by health insurance (if required).
  • Must fulfill at least 1 of the following criteria
  • Risk Stratum 1:
  • Had at least 2 hospital stays, each lasting at least \>= 24 hours, in the 12 months before enrollment, and
  • Had received systemic (not topical) antibiotics in the 12 months before enrollment, or
  • Risk Stratum 2:
  • Was anticipated to have an in-patient hospitalization for a planned surgical procedure within 60 days of enrollment. The impending hospital stay was planned to be \>= 72 hours for a surgery involving 1 of the following:
  • Kidney/bladder/urinary system
  • Musculoskeletal system
  • Respiratory system
  • Circulatory system
  • Central nervous system.

You may not qualify if:

  • Participant was pregnant, or lactating, or of childbearing potential (to be considered of non-childbearing potential, a female must be post-menopausal for at least 1 year, surgically sterile, or using an effective method of contraception or abstinence from at least 4 weeks prior to the first vaccination and until at least 4 weeks after the last vaccination).
  • Participation in the 4 weeks preceding the first trial vaccination or participation during the present trial period in another clinical trial investigating a vaccine, drug, medical device, or medical procedure.
  • Receipt of any vaccine in the 4 weeks preceding the first trial vaccination except for influenza (seasonal or pandemic) and pneumococcal vaccines. This exception includes monovalent pandemic influenza vaccines and multivalent influenza vaccines.
  • Previous vaccination against C. difficile with either the trial vaccine, another vaccine, or monoclonal antibodies.
  • Diarrhea on day of enrollment.
  • Self-reported current or prior CDI episode.
  • Anticipated or current receipt of kidney dialysis treatment.
  • History of inflammatory bowel disease, irritable bowel syndrome (must include diarrhea as a symptom), colostomy, or small or large intestine bowel surgery where resection was performed.
  • Receiving enteral feeding (e.g., nasogastric, gastrostomy, and jejunostomy tube feeding).
  • Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months).
  • Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccine used in the trial or to a vaccine containing any of the same substances.
  • Self-reported thrombocytopenia, contraindicating intramuscular vaccination.
  • Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily.
  • Current alcohol abuse or drug addiction that might interfere with the ability to comply with trial procedures in the opinion of the Investigator.
  • Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with trial conduct or completion.
  • +2 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (335)

Unknown Facility

Huntsville, Alabama, 35803, United States

Location

Investigational Site 104

Mobile, Alabama, 36608, United States

Location

Unknown Facility

Flagstaff, Arizona, 86001, United States

Location

Investigational Site 194

Phoenix, Arizona, 85018, United States

Location

Investigational Site 503

Surprise, Arizona, 85374, United States

Location

Unknown Facility

Little Rock, Arkansas, 72205, United States

Location

Unknown Facility

Bakersfield, California, 93301, United States

Location

Unknown Facility

Banning, California, 92220, United States

Location

Unknown Facility

Garden Grove, California, 92844, United States

Location

Unknown Facility

La Mesa, California, 91942, United States

Location

Investigational Site 534

Los Angeles, California, 90022, United States

Location

Investigational Site 051

Los Angeles, California, 90027, United States

Location

Unknown Facility

Modesto, California, 95350, United States

Location

Unknown Facility

Redding, California, 96001, United States

Location

Unknown Facility

Sacramento, California, 95817, United States

Location

Investigational Site 504

Simi Valley, California, 93065, United States

Location

Investigational Site 057

Stanford, California, 94305, United States

Location

Investigational Site 176

Upland, California, 91786, United States

Location

Unknown Facility

Ventura, California, 93003, United States

Location

Investigational Site 546

Wheat Ridge, Colorado, 90033, United States

Location

Unknown Facility

Bristol, Connecticut, 06010, United States

Location

Unknown Facility

Danbury, Connecticut, 06810, United States

Location

Investigational Site 143

Bradenton, Florida, 34209, United States

Location

Investigational Site 187

Brandon, Florida, 33511, United States

Location

Investigational Site 075

Clearwater, Florida, 33756, United States

Location

Investigational Site 517

Clearwater, Florida, 33765, United States

Location

Investigational Site 055

Crystal River, Florida, 34429, United States

Location

Unknown Facility

DeLand, Florida, 32720, United States

Location

Investigational Site 506

Gainesville, Florida, 32607, United States

Location

Investigational Site 099

Hialeah, Florida, 33012, United States

Location

Investigational Site 009

Jacksonville, Florida, 32216, United States

Location

Unknown Facility

Lauderdale Lakes, Florida, 33319, United States

Location

Unknown Facility

Miami, Florida, 33165, United States

Location

Unknown Facility

Orange Park, Florida, 32073, United States

Location

Investigational Site 112

Pensacola, Florida, 32504, United States

Location

Unknown Facility

Port Saint Lucie, Florida, 34987, United States

Location

Investigational Site 088

Sarasota, Florida, 34239, United States

Location

Investigational Site 040

St. Petersburg, Florida, 33709, United States

Location

Investigational Site 114

St. Petersburg, Florida, 33713, United States

Location

Unknown Facility

Tamarac, Florida, 33321, United States

Location

Unknown Facility

Tampa, Florida, 33612, United States

Location

Unknown Facility

West Palm Beach, Florida, 33401, United States

Location

Investigational Site 149

Augusta, Georgia, 30912, United States

Location

Investigational Site 529

Decatur, Georgia, 30030, United States

Location

Unknown Facility

Macon, Georgia, 31201, United States

Location

Investigational Site 010

Savannah, Georgia, 31406, United States

Location

Investigational Site 049

Idaho Falls, Idaho, 83494, United States

Location

Investigational Site 543

Pocatello, Idaho, 83201, United States

Location

Unknown Facility

Evanston, Illinois, 60201, United States

Location

Unknown Facility

Peoria, Illinois, 61602, United States

Location

Unknown Facility

Peoria, Illinois, 61614, United States

Location

Unknown Facility

Anderson, Indiana, 46011, United States

Location

Investigational Site 101

Iowa City, Iowa, 52242, United States

Location

Unknown Facility

Topeka, Kansas, 66606, United States

Location

Unknown Facility

Louisville, Kentucky, 40202, United States

Location

Investigational Site 091

Metairie, Louisiana, 70006, United States

Location

Investigational Site 084

New Orleans, Louisiana, 70121, United States

Location

Unknown Facility

Opelousas, Louisiana, 70570, United States

Location

Investigational Site 077

Shreveport, Louisiana, 71101, United States

Location

Unknown Facility

Auburn, Maine, 04210, United States

Location

Unknown Facility

Baltimore, Maryland, 21224, United States

Location

Investigational Site 002

Boston, Massachusetts, 02215, United States

Location

Investigational Site 035

West Roxbury, Massachusetts, 02132, United States

Location

Investigational Site 190

Ann Arbor, Michigan, 48106, United States

Location

Investigational Site 175

Detroit, Michigan, 48202, United States

Location

Investigational Site 183

Flint, Michigan, 48504, United States

Location

Unknown Facility

Grosse Pointe Woods, Michigan, 48236, United States

Location

Unknown Facility

Kalamazoo, Michigan, 49007, United States

Location

Unknown Facility

Livonia, Michigan, 48152, United States

Location

Investigational Site 069

Royal Oak, Michigan, 48073, United States

Location

Unknown Facility

Stevensville, Michigan, 49127, United States

Location

Unknown Facility

Troy, Michigan, 48098, United States

Location

Unknown Facility

Butte, Montana, 59701, United States

Location

Investigational Site 189

Hillsborough, New Jersey, 8844, United States

Location

Investigational Site 044

Neptune City, New Jersey, 07753, United States

Location

Unknown Facility

Teaneck, New Jersey, 07666, United States

Location

Unknown Facility

Albuquerque, New Mexico, 27103, United States

Location

Unknown Facility

Albuquerque, New Mexico, 87102, United States

Location

Investigational Site 022

Endwell, New York, 13760, United States

Location

Unknown Facility

Rochester, New York, 14621, United States

Location

Unknown Facility

Rochester, New York, 14642, United States

Location

Unknown Facility

Syracuse, New York, 13210, United States

Location

Unknown Facility

The Bronx, New York, 10467, United States

Location

Investigational Site 013

The Bronx, New York, 10468, United States

Location

Investigational Site 146

Asheville, North Carolina, 28805, United States

Location

Unknown Facility

Cary, North Carolina, 27518, United States

Location

Unknown Facility

Charlotte, North Carolina, 28209, United States

Location

Unknown Facility

Hickory, North Carolina, 28602, United States

Location

Unknown Facility

Raleigh, North Carolina, 27612, United States

Location

Unknown Facility

Raleigh, North Carolina, 48202, United States

Location

Unknown Facility

Statesville, North Carolina, 28625, United States

Location

Unknown Facility

Wilmington, North Carolina, 28401, United States

Location

Unknown Facility

Winston-Salem, North Carolina, 27103, United States

Location

Investigational Site 031

Fargo, North Dakota, 58104, United States

Location

Unknown Facility

Fargo, North Dakota, 58122, United States

Location

Investigational Site 523

Canton, Ohio, 44710, United States

Location

Unknown Facility

Cincinnati, Ohio, 45219, United States

Location

Unknown Facility

Cleveland, Ohio, 44106, United States

Location

Investigational Site 129

Cleveland, Ohio, 44109, United States

Location

Unknown Facility

Cleveland, Ohio, 44118, United States

Location

Investigational Site 003

Columbus, Ohio, 43215, United States

Location

Investigational Site 061

Dayton, Ohio, 45419, United States

Location

Unknown Facility

Dayton, Ohio, 45428, United States

Location

Unknown Facility

Kettering, Ohio, 45429, United States

Location

Unknown Facility

Marion, Ohio, 43302, United States

Location

Investigational Site 095

Middletown, Ohio, 45005, United States

Location

Unknown Facility

Bend, Oregon, 97701, United States

Location

Investigational Site 528

Camp Hill, Pennsylvania, 17011, United States

Location

Unknown Facility

Hershey, Pennsylvania, 17033, United States

Location

Unknown Facility

Philadelphia, Pennsylvania, 19140, United States

Location

Unknown Facility

Pittsburgh, Pennsylvania, 15212, United States

Location

Unknown Facility

Pittsburgh, Pennsylvania, 15240, United States

Location

Investigational Site 083

Uniontown, Pennsylvania, 15401, United States

Location

Unknown Facility

West Reading, Pennsylvania, 19611, United States

Location

Investigational Site 020

Wilkes-Barre, Pennsylvania, 18711, United States

Location

Investigational Site 050

Pawtucket, Rhode Island, 02860, United States

Location

Unknown Facility

Providence, Rhode Island, 02906, United States

Location

Unknown Facility

Providence, Rhode Island, 02908, United States

Location

Investigational Site 540

Charleston, South Carolina, 29407, United States

Location

Investigational Site 047

Mt. Pleasant, South Carolina, 29464, United States

Location

Investigational Site 180

Spartanburg, South Carolina, 29303, United States

Location

Investigational Site 086

Rapid City, South Dakota, 57701, United States

Location

Unknown Facility

Franklin, Tennessee, 37067, United States

Location

Unknown Facility

Jackson, Tennessee, 38305, United States

Location

Unknown Facility

Nashville, Tennessee, 37082, United States

Location

Unknown Facility

Nashville, Tennessee, 37203, United States

Location

Investigational Site 544

Austin, Texas, 78726, United States

Location

Unknown Facility

Corpus Christi, Texas, 78413, United States

Location

Investigational Site 006

Dallas, Texas, 75216, United States

Location

Investigational Site 119

Fort Worth, Texas, 76104, United States

Location

Unknown Facility

Groesbeck, Texas, 76642, United States

Location

Investigational Site 193

San Antonio, Texas, 78229, United States

Location

Unknown Facility

Tomball, Texas, 77375, United States

Location

Investigational Site 135

Orem, Utah, 84058, United States

Location

Investigational Site 080

Salt Lake City, Utah, 84124, United States

Location

Investigational Site 012

Lynchburg, Virginia, 24501, United States

Location

Unknown Facility

Williamsburg, Virginia, 23185, United States

Location

Investigational Site 196

Winchester, Virginia, 22601, United States

Location

Unknown Facility

Spokane, Washington, 99202, United States

Location

Unknown Facility

Tacoma, Washington, 98405, United States

Location

Investigational Site 030

Marshfield, Wisconsin, 54449, United States

Location

Unknown Facility

Weston, Wisconsin, 54476, United States

Location

Unknown Facility

Westmead, New South Wales, 2145, Australia

Location

Investigational Site 401

Cairns, Queensland, 4870, Australia

Location

Unknown Facility

Woolloongabba, Queensland, 4102, Australia

Location

Investigational Site 404

Bedford Park, South Australia, 5042, Australia

Location

Investigational Site 403

Clayton, Victoria, 3168, Australia

Location

Unknown Facility

Nedlands, Western Australia, 6009, Australia

Location

Unknown Facility

Subiaco, Western Australia, 6008, Australia

Location

Unknown Facility

Salvador, Estado de Bahia, 40420-000, Brazil

Location

Unknown Facility

Salvador, Estado de Bahia, 41253-190, Brazil

Location

Unknown Facility

Aparecida de Goiânia, Goiás, 74935-530, Brazil

Location

Unknown Facility

Belo Horizonte, Minas Gerais, 30150-221, Brazil

Location

Unknown Facility

Belo Horizonte, Minas Gerais, 30190-130, Brazil

Location

Unknown Facility

Juiz de Fora, Minas Gerais, 36010-570, Brazil

Location

Unknown Facility

Curitiba, Paraná, 80810-040, Brazil

Location

Unknown Facility

Recife, Pernambuco, 52020-010, Brazil

Location

Unknown Facility

Nova Iguaçu, Rio de Janeiro, 26030-380, Brazil

Location

Unknown Facility

Rio de Janeiro, Rio de Janeiro, 22271-100, Brazil

Location

Unknown Facility

Natal, Rio Grande do Norte, 59025-600, Brazil

Location

Unknown Facility

Canoas, Rio Grande do Sul, 92425-900, Brazil

Location

Unknown Facility

Porto Alegre, Rio Grande do Sul, 90035-003, Brazil

Location

Unknown Facility

Santo André, São Paulo, 09060-650, Brazil

Location

Unknown Facility

Campinas, 13020431, Brazil

Location

Unknown Facility

New Westminster, British Columbia, V3L 3W7, Canada

Location

Investigational Site 156

Surrey, British Columbia, V3V 1Z2, Canada

Location

Investigational Site 158

Vancouver, British Columbia, V5Z IM9, Canada

Location

Unknown Facility

Winnipeg, Manitoba, R3A IR9, Canada

Location

Unknown Facility

Halifax, Nova Scotia, B3K 6R8, Canada

Location

Investigational Site 163

Truro, Nova Scotia, B2N 1L2, Canada

Location

Unknown Facility

Guelph, Ontario, N1H 1B1, Canada

Location

Unknown Facility

Toronto, Ontario, M5G 1X5, Canada

Location

Unknown Facility

Montreal, Quebec, H3T 1E2, Canada

Location

Unknown Facility

Pierrefonds, Quebec, H9H 4Y6, Canada

Location

Investigational Site 152

Québec, Quebec, G1E 7G9, Canada

Location

Investigational Site 151

Sherbrooke, Quebec, J1H5N4, Canada

Location

Investigational Site 161

Trois-Rivières, Quebec, G8Z 3R9, Canada

Location

Unknown Facility

Barranquilla, Alantico, Colombia

Location

Unknown Facility

Medellín, Antioquia, Colombia

Location

Unknown Facility

Bogotá, Ditrito Capital, Colombia

Location

Unknown Facility

Bogotá, Ditrito, Colombia

Location

Unknown Facility

Armenia, Quindío Department, Colombia

Location

Unknown Facility

Bucaramanga, Santander Department, Colombia

Location

Unknown Facility

Floridablanca, Santander Department, Colombia

Location

Unknown Facility

Yopal, Colombia

Location

Unknown Facility

San José, 250-1000, Costa Rica

Location

Investigational Site 215

Aarhus, 8200, Denmark

Location

Investigational Site 347

Santo Domingo, Dominican Republic

Location

Unknown Facility

Espoo, FIN-02100, Finland

Location

Unknown Facility

Helsinki, FIN-00100, Finland

Location

Unknown Facility

Helsinki, FIN-00930, Finland

Location

Investigational Site 203

Jarvenpaa, FIN-04400, Finland

Location

Unknown Facility

Kokkola, 67100, Finland

Location

Unknown Facility

Oulu, FIN-90220, Finland

Location

Unknown Facility

Pori, 28100, Finland

Location

Unknown Facility

Seinäjoki, 60100, Finland

Location

Investigational Site 201

Tampere, FIN-33100, Finland

Location

Investigational Site 202

Turku, FIN-20520, Finland

Location

Unknown Facility

Vantaa, FIN-01300, Finland

Location

Investigational Site 230

Dijon, 21079, France

Location

Unknown Facility

Lille, 49100, France

Location

Unknown Facility

Limoges, 87042, France

Location

Unknown Facility

Lyon, 69004, France

Location

Unknown Facility

Montpellier, 34295, France

Location

Unknown Facility

Orléans, 45100, France

Location

Investigational Site 221

Paris, 75014, France

Location

Investigational Site 229

Pringy, 21079, France

Location

Unknown Facility

Saint-Etienne, 42055, France

Location

Investigational Site 223

Saint-Priest-en-Jarez, 42270, France

Location

Unknown Facility

Tourcoing, 59208, France

Location

Investigational Site 232

Tours, 37044, France

Location

Investigational Site 244

Deggingen, Baden-Wurttemberg, 73326, Germany

Location

Unknown Facility

Munich, Bavaria, 81675, Germany

Location

Investigational Site 242

Würzburg, Bavaria, 97074, Germany

Location

Unknown Facility

Cologne, North Rhine-Westphalia, 50937, Germany

Location

Unknown Facility

Leipzig, Saxony, 04109, Germany

Location

Unknown Facility

Jena, Thuringia, 07747, Germany

Location

Unknown Facility

Berlin, 10629, Germany

Location

Unknown Facility

Berlin, 13347, Germany

Location

Unknown Facility

Essen, 45355, Germany

Location

Unknown Facility

Goch, 47574, Germany

Location

Investigational Site 247

Hamburg, 20359, Germany

Location

Investigational Site 245

Hamburg, 22143, Germany

Location

Unknown Facility

Leipzig, 97074, Germany

Location

Unknown Facility

Guatemala City, 1001, Guatemala

Location

Investigational Site 450

Aichi, 491-8551, Japan

Location

Investigational Site 468

Chiba, 278-0004, Japan

Location

Investigational Site 467

Fukui, 910-0067, Japan

Location

Investigational Site 464

Fukuoka, 800-0344, Japan

Location

Investigational Site 465

Fukuoka, 814-8525, Japan

Location

Investigational Site 466

Fukuoka, 838-0069, Japan

Location

Investigational Site 457

Gunma, 371-0014, Japan

Location

Investigational Site 455

Hyōgo, 666-0125, Japan

Location

Investigational Site 453

Ibaraki, 300-0028, Japan

Location

Investigational Site 460

Kyoto, 611-0041, Japan

Location

Investigational Site 454

Kyoto, 613-0034, Japan

Location

Investigational Site 456

Nagano, 382-0091, Japan

Location

Investigational Site 452

Nagano, 390-8601, Japan

Location

Investigational Site 458

Nagano, 392-8510, Japan

Location

Investigational Site 469

Okinawa, 904-2293, Japan

Location

Investigational Site 461

Ōsaka, 596-8522, Japan

Location

Investigational Site 459

Saitama, 348-0044, Japan

Location

Investigational Site 467

Shimonoseki, 750-8520, Japan

Location

Investigational Site 451

Tokyo, 171-0014, Japan

Location

Investigational Site 463

Yamaguchi, 750-8520, Japan

Location

Unknown Facility

Aguascalientes, Aguascalientes, 20230, Mexico

Location

Investigational Site 325

Mexico City, D.F., 14000, Mexico

Location

Investigational Site 329

Mexico City, D.F., 14080, Mexico

Location

Unknown Facility

Tijuana, Estado de Baja California, 22320, Mexico

Location

Investigational Site 324

Guadalajara, Jalisco, 44280, Mexico

Location

Investigational Site 351

Cuernavaca, Morelos, 62290, Mexico

Location

Unknown Facility

Monterrey, Nuevo León, 64460, Mexico

Location

Unknown Facility

San Luis Potosí City, San Luis Potosí, 78240, Mexico

Location

Investigational Site 352

Ecatepec de Morelos, State of Mexico, 55076, Mexico

Location

Investigational Site 363

Ciudad Victoria, Tamaulipas, Mexico

Location

Investigational Site 326

Durango, 34000, Mexico

Location

Unknown Facility

Morelos, Mexico

Location

Unknown Facility

San Luis Potosí City, 78240, Mexico

Location

Investigational Site 354

Panama City, Panama

Location

Investigational Site 364

Trujillo, La Libertad, 130101, Peru

Location

Investigational Site 332

Jesus Maria, Lima region, lima 11, Peru

Location

Unknown Facility

Lima Cercado, Lima region, Peru

Location

Investigational Site 334

San Martín de Porres, Lima region, lima 31, Peru

Location

Unknown Facility

Surquillo, Lima region, Peru

Location

Investigational Site 356

Lima, callao 2, Peru

Location

Investigational Site 355

Lima, lima 1, Peru

Location

Unknown Facility

Lima, Peru

Location

Investigational Site 365

Piura, 200101, Peru

Location

Unknown Facility

Alabang, 1770, Philippines

Location

Unknown Facility

Dasmariñas, 4114, Philippines

Location

Unknown Facility

Manila, 1000, Philippines

Location

Unknown Facility

Manila, 1004, Philippines

Location

Unknown Facility

Pasig, 1600, Philippines

Location

Unknown Facility

Quezon City, 1100, Philippines

Location

Unknown Facility

Quezon City, 1101, Philippines

Location

Investigational Site 284

Bydgoszcz, 85-863, Poland

Location

Investigational Site 283

Nowy Duninów, 09-505, Poland

Location

Investigational Site 171

Bayamón, PR, 00960, Puerto Rico

Location

Unknown Facility

Bayamón, 00961, Puerto Rico

Location

Unknown Facility

Singapore, 119074, Singapore

Location

Investigational Site 419

Singapore, 119228, Singapore

Location

Unknown Facility

Singapore, 169608, Singapore

Location

Investigational Site 428

Singapore, 308433, Singapore

Location

Investigational Site 445

Singapore, 768828, Singapore

Location

Unknown Facility

Seoul, Gangnam-gu, 135-710, South Korea

Location

Investigational Site 407

Wŏnju, Gangwon-do, 26427, South Korea

Location

Investigational Site 413

Ansan, Gyeonggi-do, 15355, South Korea

Location

Unknown Facility

Daegu, Jung-Gu, 700-721, South Korea

Location

Investigational Site 427

Incheon, Namdong-gu, 22332, South Korea

Location

Unknown Facility

Seoul, Seocho-gu, 137-701, South Korea

Location

Unknown Facility

Seoul, Seodaemun-gu, 120-752, South Korea

Location

Unknown Facility

Seoul, Seongbuk-gu, 136-705, South Korea

Location

Unknown Facility

Seoul, Seongdong-gu, 132-792, South Korea

Location

Unknown Facility

Seoul, Songpa-gu, 138-736, South Korea

Location

Investigational Site 446

Busan, 49201, South Korea

Location

Unknown Facility

Cheongju-si, 361-711, South Korea

Location

Investigational Site 439

Gyeonggi-do, 16247, South Korea

Location

Unknown Facility

Gyeonggi-do, 443-380, South Korea

Location

Investigational Site 412

Incheon, 21565, South Korea

Location

Investigational Site 409

Seoul, 2841, South Korea

Location

Investigational Site 408

Seoul, 3722, South Korea

Location

Investigational Site 415

Seoul, 5355, South Korea

Location

Investigational Site 418

Seoul, 5505, South Korea

Location

Investigational Site 411

Seoul, 6351, South Korea

Location

Investigational Site 437

Seoul, 7441, South Korea

Location

Investigational Site 438

Seoul, 8308, South Korea

Location

Investigational Site 294

Córdoba, 14004, Spain

Location

Investigational Site 293

Santander, 39008, Spain

Location

Investigational Site 292

Terrassa, 08221, Spain

Location

Investigational Site 295

Vigo, 36312, Spain

Location

Unknown Facility

Göthenburg, SWE, 41685, Sweden

Location

Unknown Facility

Stockholm, 11157, Sweden

Location

Unknown Facility

Umeå, 90185, Sweden

Location

Unknown Facility

Kaohsiung City, 813, Taiwan

Location

Investigational Site 426

New Taipei City, 22056, Taiwan

Location

Unknown Facility

New Taipei City, 23156, Taiwan

Location

Investigational Site 429

Taichung, 40201, Taiwan

Location

Investigational Site 421

Tainan, 71004, Taiwan

Location

Investigational Site 425

Taipei, 10002, Taiwan

Location

Unknown Facility

Tiachung, 404, Taiwan

Location

Investigational Site 443

Bangkok, 10330, Thailand

Location

Investigational Site 442

Bangkok, 10400, Thailand

Location

Investigational Site 441

Khon Kaen, 40002, Thailand

Location

Investigational Site 276

Blackpool, FY3 7EN, United Kingdom

Location

Unknown Facility

Blackpool, FY3 8NR, United Kingdom

Location

Investigational Site 277

Coventry, CV2 2DX, United Kingdom

Location

Unknown Facility

Harrow, HA1 3UJ, United Kingdom

Location

Investigational Site 281

Leeds, LS9 7TF, United Kingdom

Location

Unknown Facility

Liverpool, L78XP, United Kingdom

Location

Investigational Site 271

London, SW17 0RE, United Kingdom

Location

Unknown Facility

Manchester, M8 5RB, United Kingdom

Location

Unknown Facility

Middlesex, HA1 3UJ, United Kingdom

Location

Unknown Facility

North Shields, NE29 8NH, United Kingdom

Location

Investigational Site 275

Penzance, TR19 7HX, United Kingdom

Location

Unknown Facility

Stoke-on-Trent, SR53SY, United Kingdom

Location

Related Publications (1)

  • de Bruyn G, Gordon DL, Steiner T, Tambyah P, Cosgrove C, Martens M, Bassily E, Chan ES, Patel D, Chen J, Torre-Cisneros J, Fernando De Magalhaes Francesconi C, Gesser R, Jeanfreau R, Launay O, Laot T, Morfin-Otero R, Oviedo-Orta E, Park YS, Piazza FM, Rehm C, Rivas E, Self S, Gurunathan S. Safety, immunogenicity, and efficacy of a Clostridioides difficile toxoid vaccine candidate: a phase 3 multicentre, observer-blind, randomised, controlled trial. Lancet Infect Dis. 2021 Feb;21(2):252-262. doi: 10.1016/S1473-3099(20)30331-5. Epub 2020 Sep 15.

MeSH Terms

Conditions

Clostridium Infections

Interventions

Saline Solution

Condition Hierarchy (Ancestors)

Gram-Positive Bacterial InfectionsBacterial InfectionsBacterial Infections and MycosesInfections

Intervention Hierarchy (Ancestors)

Crystalloid SolutionsIsotonic SolutionsSolutionsPharmaceutical Preparations

Results Point of Contact

Title
Medical Director
Organization
Sanofi Pasteur

Study Officials

  • Medical Director

    Sanofi Pasteur Inc.

    STUDY DIRECTOR

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
OTHER
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Model Details: This study was observer-blind. The vaccine preparer and administrator may have been unblinded to treatment assignment due to the steps necessary for vaccine preparation. However, the participant, the Investigator, and study staff members who collected the safety data and laboratory personnel who analyzed the blood and stool samples were all blinded to the group assignment.
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 20, 2013

First Posted

June 27, 2013

Study Start

July 30, 2013

Primary Completion

June 12, 2018

Study Completion

June 12, 2018

Last Updated

March 28, 2022

Results First Posted

July 5, 2019

Record last verified: 2022-03

Data Sharing

IPD Sharing
Will share

Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

Locations